BibTex RIS Cite

-

Year 2013, Volume: 26 Issue: 1, 17 - 20, 30.09.2015

Abstract

Objective: To compare the efficacy of nadifloxacin alone and with benzoyl peroxide in the treatment of mild to moderate facial acne vulgaris. Patients and Methods: This double-blind, randomized study was conducted in a total of 93 acne patients, with at least 10 inflammatory lesions, but no more than 3 nodules or cysts on the face. All patients were instructed to apply nadifloxacin 1% cream twice daily and randomized to apply either benzoyl peroxide 5% lotion or its vehicle once daily for 8 weeks. Results: The mean percent reduction in inflammatory lesions were 22.08% in the nadifloxacin group (n=46) and 53.5% in the nadifloxacin+benzoyl peroxide group (n=47). Five (10.9%) patients in the nadifloxacin group and 18 (38.3%) patients in the nadifloxacin+benzoyl peroxide group achieved a 50% and greater reduction in the inflammatory lesion count. Conclusion: Both treatment regimens were statistically effective, but a significantly greater reduction of the inflammatory lesions was seen in the nadifloxacin+benzoyl peroxide group. The number of patients who achieved a 50% and greater reduction in inflammatory lesion count was significantly higher in the nadifloxacin+benzoyl peroxide group. Both treatment regimens were well tolerated with mild side effects

References

  • 1. Thiboutat D, Gollnick H, Bettoli V, et al. New insights into the managements of acne: an update from the Global Alliance to improve outcomes in acne group. J Am Acad Dermatol 2009; 60 (5 Suppl): S1- 50. doi: 10.1016/j.jaad.2009.01.019
  • 2. Gollnick H, Cunliffe W, Berson D, et al. Global alliance to improve outcomes in acne. J Am Acad Dermatol 2003; 49 (1 Suppl): S1-37.
  • 3. Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. Br J Dermatol 2001; 144: 339-46. doi:10.1046/j.1365-2133.2001.03956.x
  • 4. Leyden J, Levy S. The development of antibiotic resistance in Propionibacterium acnes in acne. Cutis 2001; 67 (2 suppl): 21-4.
  • 5. Coates P, Vyakrnam S, Eady EA, et al. Prevelance of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distrubution study. Br J Dermatol 2002; 146: 840-8. doi:10.1046/j.1365-2133.2002.04690.x
  • 6. Kawabata S, Ohguro K, Mukai F, et al. Bacteriological evaluation of OPC-7251, a new pyridone carboxylic acid antimicrobial agent. 1: In vitro antibacterial activity. Chemotherapy 1989; 37: 1160-78.
  • 7. Kurukawa I, Akamatsu H, Nishijima S, et al. Clinical and bacteriologic evalution of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base. J am Acad Dermatol 1991; 25: 674-81.
  • 8. Jung JY, Kwan HH, Yeau KB, et al. Clinical and histological evalution of 1% nadifloxacin cream in the treatment of acne vulgaris in Korean patients. Int J Dermatol 2011; 50:350-7. doi:10.1111/j.1365- 4632.2010.04701.x
  • 9. Plewig G, Holland KT, Nenoff P. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a doubleblind, phase 3 comparison study versus erythromycin 2% cream. Eur J Dermatol 2006; 16 : 48-55. doi:10.1586/17469872.1.5.643
  • 10. Tunca M, Akar A, Ozmen I, et al. Topical nadifloxacin 1% cream vs. topical erythromycin 4% jel in the treatment of mild to moderate acne. Int J Dermatol 2010; 45:1440-4. doi:10.1111/j.1365- 4632.2010.04601.x
  • 11. Bojar RA, Hittel N, Cunliffe WJ, et al. Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin. Drugs 1995; 49 (Suppl 2): 164- 7.
  • 12. Alba V, Urban E, Dominguez A, et al. In vitro activity of nadifloxacin against several Gram-positive bacteria and analsis of the possible evalution of resistance after 2 years of use in Germany. Int J Antimicrob Agent 2009; 33: 272-5. doi:10.1016/j.ijantimicag.2008.08.024
  • 13. Thiboutat D, Zaenglein A, Weiss J, et al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: Assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol 2008; 6: 1-9.
  • 14. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, doubleblind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol 2006, 54: 73-81. doi:10.1016/j.jaad.2005.04.046
  • 15. Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol 2005; 153: 395-403.
  • 16. Eady EA, Cove JH, Joanes DN. Topical antibiotics for the treatment of acne vulgaris: a critical evaluation of literature on their clinical benefit and comparative efficacy. J Dermatolog Treat 1990; 1: 215-26. doi:10.3109/09546639009086737
  • 17. Thiboutot D, Weiss J, Bucko A, Jones T. Adapalene-benzoyl peroxide, a fixed dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007; 57: 791-9. doi:10.1016/j.jaad.2007.06.006
  • 18. Cunliffe WJ, Holland KT, Bojar R. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 2002; 24: 1117-33. doi:10.1016/S0149- 2918(02)80023-6
  • 19. Ozolins M, Eady EA, Avery A, Cunliffe WJ. Comparison of five antimicrobial regimens for the treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomized controlled trial. Lancet 2004; 364: 2188-95. doi:10.1016/S0140- 6736(04)17591-0
  • 20. Ghali F, Kang S, Leyden JJ, et al. Changing the face of acne therapy. Cutis 2009; 83 (2 Suppl): 4-15.
  • 21. Worret WI, Fluhr JW. Acne therapy with topical benzoyl peroxide, antibiotics and azelaic acid. JDDG 2006; 4: 293-300. doi:10.1111/ j.1610-0387.2006.05931suppl.x

Hafif-orta şiddetli akne vulgaris yüz tutulumu tedavisinde nadifloksasinin tek başına ve benzoil peroksit ile birlikte kullanımının karşılaştırılması

Year 2013, Volume: 26 Issue: 1, 17 - 20, 30.09.2015

Abstract

Amaç: Hafif-orta şiddetli akne vulgaris tedavisinde nadifloksasin
kremin tek başına veya benzoil peroksit ile birlikte kullanımının
etkinliğini karşılaştırma.
Hastalar ve Yöntem: Çift kör, randomize çalışma, toplam
93 hasta 2 grup olarak ya nadifloksasin kremi ya benzoil peroksit
losyonun baz formu ya da benzoil peroksit ile birlikte 8 hafta süre
ile kullandı.
Bulgular: İnflamatuar lezyonlar tek başına nadifloksasin
kullanan grupta(n=46) %22, 08, nadifloksasin+benzoil peroksit
kullanan grupta(n=47) %53,5 oranında azaldı. Tek başına
nadifloksasin kullanan grupta beş (%10,9), nadifloksasin+benzoil
peroksit kullanan grupta 18(%38,3)hastada inflamatuar lezyonlarda
%50 ve üzeri azalma görüldü.
Sonuç: Her iki tedavi de istatistiksel olarak etkili bulundu ancak
nadifloksasin+benzoil peroksit grubunda belirgin olarak inflamatuar
lezyonlarda azalma görüldü. Her iki tedavi de hafif yan etkiler ile
çok iyi tolere edildi

References

  • 1. Thiboutat D, Gollnick H, Bettoli V, et al. New insights into the managements of acne: an update from the Global Alliance to improve outcomes in acne group. J Am Acad Dermatol 2009; 60 (5 Suppl): S1- 50. doi: 10.1016/j.jaad.2009.01.019
  • 2. Gollnick H, Cunliffe W, Berson D, et al. Global alliance to improve outcomes in acne. J Am Acad Dermatol 2003; 49 (1 Suppl): S1-37.
  • 3. Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. Br J Dermatol 2001; 144: 339-46. doi:10.1046/j.1365-2133.2001.03956.x
  • 4. Leyden J, Levy S. The development of antibiotic resistance in Propionibacterium acnes in acne. Cutis 2001; 67 (2 suppl): 21-4.
  • 5. Coates P, Vyakrnam S, Eady EA, et al. Prevelance of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distrubution study. Br J Dermatol 2002; 146: 840-8. doi:10.1046/j.1365-2133.2002.04690.x
  • 6. Kawabata S, Ohguro K, Mukai F, et al. Bacteriological evaluation of OPC-7251, a new pyridone carboxylic acid antimicrobial agent. 1: In vitro antibacterial activity. Chemotherapy 1989; 37: 1160-78.
  • 7. Kurukawa I, Akamatsu H, Nishijima S, et al. Clinical and bacteriologic evalution of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base. J am Acad Dermatol 1991; 25: 674-81.
  • 8. Jung JY, Kwan HH, Yeau KB, et al. Clinical and histological evalution of 1% nadifloxacin cream in the treatment of acne vulgaris in Korean patients. Int J Dermatol 2011; 50:350-7. doi:10.1111/j.1365- 4632.2010.04701.x
  • 9. Plewig G, Holland KT, Nenoff P. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a doubleblind, phase 3 comparison study versus erythromycin 2% cream. Eur J Dermatol 2006; 16 : 48-55. doi:10.1586/17469872.1.5.643
  • 10. Tunca M, Akar A, Ozmen I, et al. Topical nadifloxacin 1% cream vs. topical erythromycin 4% jel in the treatment of mild to moderate acne. Int J Dermatol 2010; 45:1440-4. doi:10.1111/j.1365- 4632.2010.04601.x
  • 11. Bojar RA, Hittel N, Cunliffe WJ, et al. Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin. Drugs 1995; 49 (Suppl 2): 164- 7.
  • 12. Alba V, Urban E, Dominguez A, et al. In vitro activity of nadifloxacin against several Gram-positive bacteria and analsis of the possible evalution of resistance after 2 years of use in Germany. Int J Antimicrob Agent 2009; 33: 272-5. doi:10.1016/j.ijantimicag.2008.08.024
  • 13. Thiboutat D, Zaenglein A, Weiss J, et al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: Assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol 2008; 6: 1-9.
  • 14. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, doubleblind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol 2006, 54: 73-81. doi:10.1016/j.jaad.2005.04.046
  • 15. Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol 2005; 153: 395-403.
  • 16. Eady EA, Cove JH, Joanes DN. Topical antibiotics for the treatment of acne vulgaris: a critical evaluation of literature on their clinical benefit and comparative efficacy. J Dermatolog Treat 1990; 1: 215-26. doi:10.3109/09546639009086737
  • 17. Thiboutot D, Weiss J, Bucko A, Jones T. Adapalene-benzoyl peroxide, a fixed dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007; 57: 791-9. doi:10.1016/j.jaad.2007.06.006
  • 18. Cunliffe WJ, Holland KT, Bojar R. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 2002; 24: 1117-33. doi:10.1016/S0149- 2918(02)80023-6
  • 19. Ozolins M, Eady EA, Avery A, Cunliffe WJ. Comparison of five antimicrobial regimens for the treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomized controlled trial. Lancet 2004; 364: 2188-95. doi:10.1016/S0140- 6736(04)17591-0
  • 20. Ghali F, Kang S, Leyden JJ, et al. Changing the face of acne therapy. Cutis 2009; 83 (2 Suppl): 4-15.
  • 21. Worret WI, Fluhr JW. Acne therapy with topical benzoyl peroxide, antibiotics and azelaic acid. JDDG 2006; 4: 293-300. doi:10.1111/ j.1610-0387.2006.05931suppl.x
There are 21 citations in total.

Details

Primary Language Turkish
Journal Section Articles
Authors

Züleyha Özgen This is me

Oya Gürbüz This is me

Publication Date September 30, 2015
Published in Issue Year 2013 Volume: 26 Issue: 1

Cite

APA Özgen, Z., & Gürbüz, O. (2015). Hafif-orta şiddetli akne vulgaris yüz tutulumu tedavisinde nadifloksasinin tek başına ve benzoil peroksit ile birlikte kullanımının karşılaştırılması. Marmara Medical Journal, 26(1), 17-20.
AMA Özgen Z, Gürbüz O. Hafif-orta şiddetli akne vulgaris yüz tutulumu tedavisinde nadifloksasinin tek başına ve benzoil peroksit ile birlikte kullanımının karşılaştırılması. Marmara Med J. October 2015;26(1):17-20.
Chicago Özgen, Züleyha, and Oya Gürbüz. “Hafif-Orta şiddetli Akne Vulgaris yüz Tutulumu Tedavisinde Nadifloksasinin Tek başına Ve Benzoil Peroksit Ile Birlikte kullanımının karşılaştırılması”. Marmara Medical Journal 26, no. 1 (October 2015): 17-20.
EndNote Özgen Z, Gürbüz O (October 1, 2015) Hafif-orta şiddetli akne vulgaris yüz tutulumu tedavisinde nadifloksasinin tek başına ve benzoil peroksit ile birlikte kullanımının karşılaştırılması. Marmara Medical Journal 26 1 17–20.
IEEE Z. Özgen and O. Gürbüz, “Hafif-orta şiddetli akne vulgaris yüz tutulumu tedavisinde nadifloksasinin tek başına ve benzoil peroksit ile birlikte kullanımının karşılaştırılması”, Marmara Med J, vol. 26, no. 1, pp. 17–20, 2015.
ISNAD Özgen, Züleyha - Gürbüz, Oya. “Hafif-Orta şiddetli Akne Vulgaris yüz Tutulumu Tedavisinde Nadifloksasinin Tek başına Ve Benzoil Peroksit Ile Birlikte kullanımının karşılaştırılması”. Marmara Medical Journal 26/1 (October 2015), 17-20.
JAMA Özgen Z, Gürbüz O. Hafif-orta şiddetli akne vulgaris yüz tutulumu tedavisinde nadifloksasinin tek başına ve benzoil peroksit ile birlikte kullanımının karşılaştırılması. Marmara Med J. 2015;26:17–20.
MLA Özgen, Züleyha and Oya Gürbüz. “Hafif-Orta şiddetli Akne Vulgaris yüz Tutulumu Tedavisinde Nadifloksasinin Tek başına Ve Benzoil Peroksit Ile Birlikte kullanımının karşılaştırılması”. Marmara Medical Journal, vol. 26, no. 1, 2015, pp. 17-20.
Vancouver Özgen Z, Gürbüz O. Hafif-orta şiddetli akne vulgaris yüz tutulumu tedavisinde nadifloksasinin tek başına ve benzoil peroksit ile birlikte kullanımının karşılaştırılması. Marmara Med J. 2015;26(1):17-20.